GDERF — Galderma Group AG/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2021390 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 13,393,000,000 | 780,000,000 | 5,244,000,000 |
| Jun 2025 | — | — | — | — | 12,877,000,000 | 458,000,000 | 5,147,000,000 |
| Dec 2024 | — | — | — | — | 12,617,000,000 | 457,000,000 | 4,827,000,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$6,347,000,000
Inventory
$525,000,000
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,922,999,808
EBITDA
$1,386,000,000
Free Cash Flow
$874,625,024
Enterprise Value
$44,755,783,680
Total Cash
$839,000,000
Total Debt
$2,716,000,000
Shares Out
233,188,937
Trailing EPS
$3.64
Book Value
$35.23
ROE
10.8%
ROA
5.4%
Div Yield
0.24%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,241,000,000 | 876,000,000 | 613,000,000 | 13,393,000,000 | 5,244,000,000 | 8,150,000,000 | 1,185,000,000 |
| Dec 2024 | 4,440,000,000 | 678,000,000 | 231,000,000 | 12,617,000,000 | 4,827,000,000 | 7,790,000,000 | 488,000,000 |
| Dec 2023 | 4,117,000,000 | 611,000,000 | -57,000,000 | 12,471,000,000 | 7,102,000,000 | 5,369,000,000 | 165,000,000 |
| Dec 2022 | 3,823,900,000 | 406,000,000 | -98,500,000 | — | — | — | 111,300,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRRN | Bryn Inc. | $945.00B | $2100.00 | — |
| SPY | SPDR S&P 500 ETF TRUST | $710.30B | $773.93 | — |
| KLAC | KLA CORP | $257.02B | $196.72 | — |
| TMO | THERMO FISHER SCIENTIFIC INC. | $241.07B | $651.98 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $213.50B | $226.61 | — |
News headlines (Yahoo Finance, 1h cache)
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
2026-10-08 05:00 · Yahoo
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
2026-10-06 05:00 · Yahoo
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
2026-09-30 05:00 · Yahoo
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
2026-09-23 05:00 · Yahoo
Why Galderma Group (SWX:GALD) Is Getting Attention Today
2026-09-22 01:15 · Yahoo
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
2026-09-21 05:00 · Yahoo
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
2026-09-16 05:00 · Yahoo
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
2026-09-08 10:58 · Yahoo
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
2026-08-11 05:00 · Yahoo
Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook
2026-07-30 13:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.